Porta-Pardo Eduard, Garcia-Alonso Luz, Hrabe Thomas, Dopazo Joaquin, Godzik Adam
Bioinformatics and Systems Biology Program, Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America.
European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, United Kingdom.
PLoS Comput Biol. 2015 Oct 20;11(10):e1004518. doi: 10.1371/journal.pcbi.1004518. eCollection 2015 Oct.
Despite their importance in maintaining the integrity of all cellular pathways, the role of mutations on protein-protein interaction (PPI) interfaces as cancer drivers has not been systematically studied. Here we analyzed the mutation patterns of the PPI interfaces from 10,028 proteins in a pan-cancer cohort of 5,989 tumors from 23 projects of The Cancer Genome Atlas (TCGA) to find interfaces enriched in somatic missense mutations. To that end we use e-Driver, an algorithm to analyze the mutation distribution of specific protein functional regions. We identified 103 PPI interfaces enriched in somatic cancer mutations. 32 of these interfaces are found in proteins coded by known cancer driver genes. The remaining 71 interfaces are found in proteins that have not been previously identified as cancer drivers even that, in most cases, there is an extensive literature suggesting they play an important role in cancer. Finally, we integrate these findings with clinical information to show how tumors apparently driven by the same gene have different behaviors, including patient outcomes, depending on which specific interfaces are mutated.
尽管突变在维持所有细胞通路完整性方面具有重要作用,但作为癌症驱动因素的蛋白质-蛋白质相互作用(PPI)界面上的突变作用尚未得到系统研究。在此,我们分析了来自癌症基因组图谱(TCGA)23个项目的5989个肿瘤的泛癌队列中10028种蛋白质的PPI界面的突变模式,以寻找富含体细胞错义突变的界面。为此,我们使用了e-Driver,一种分析特定蛋白质功能区域突变分布的算法。我们鉴定出103个富含体细胞癌突变的PPI界面。其中32个界面存在于已知癌症驱动基因编码的蛋白质中。其余71个界面存在于先前未被鉴定为癌症驱动因素的蛋白质中,即便在大多数情况下,有大量文献表明它们在癌症中发挥重要作用。最后,我们将这些发现与临床信息相结合,以展示表面上由同一基因驱动的肿瘤如何根据特定突变的界面呈现出不同行为,包括患者预后。